Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.2 (
topoisomerase
)
9,166
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Methods of uncoupling the DNA binding, cleavage and religation reactions of
topoisomerase
II were employed to investigate the influence of
topoisomerase
II-directed drugs on the individual steps in the enzyme's catalytic cycle. A special DNA substrate containing a major
topoisomerase
II interaction site, which can be cleaved by the enzyme in the absence of any concomitant religation, was used to examine the effect of
topoisomerase
II-directed agents upon the DNA cleavage reaction. The experiment demonstrated that the
topoisomerase
II targeting agent Ro 15-0216 stimulates the DNA cleavage reaction extensively, whereas the traditional
topoisomerase
II inhibitor, mAMSA, has only a minor effect on this reaction. Topoisomerase II trapped in the cleavage complexes can religate to the 3' hydroxyl end of another DNA strand. Using this religation assay, it was demonstrated that the major effect of mAMSA is an inhibition of the enzyme's religation reaction, whereas Ro 15-0216 has no effect on this reaction. Recently, considerable attention has been given to drugs preventing
topoisomerase
II from introducing DNA cleavages. In the present paper the initial non-covalent DNA binding reaction of
topoisomerase
II was investigated under conditions excluding enzyme-mediated DNA cleavage. This demonstrated that the anthracycline, aclarubicin, prevents
topoisomerase
II from performing its initial non-covalent DNA binding reaction and thereby abolishes the DNA cleavage reaction of the enzyme. The results presented here demonstrate that profound differences exist in the mode of action of different agents targeting
topoisomerase
II, and that the enzyme can be affected by such agents at both its DNA binding, cleavage and religation subreactions.
J Mol Biol 1992
Dec
05
PMID:Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. 133 85
The DNA intercalating, ellipticine analog drug, 5,11-dimethyl-5H-indol[2,3-b]quinoline, is able to stabilize in vitro the
topoisomerase
II-DNA cleavable complex and to induce DNA breaks in BPV I episome in rat fibroblasts. Cytotoxicity studies with DC3F cells resistant to ellipticine strongly suggest that
topoisomerase
II is a cellular target involved in the mechanism of cytotoxic action of this carboline derivative.
Biochem Pharmacol 1992
Dec
01
PMID:A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. 133 51
Fifteen specific inhibitors of DNA topoisomerases I and II were used to elucidate whether these enzymes participate in the excision repair of UV-induced DNA damage, monitoring DNA repair synthesis in confluent saponin-permeabilized human fibroblasts. To achieve a sufficient degree of accuracy dose--response experiments were performed, analysed by linear regression, and the concentrations at which repair activity was reduced to 50% were calculated and designated K50. Camptothecin, a specific inhibitor of topoisomerase I did not markedly diminish DNA repair synthesis. Similarly, when combined with
topoisomerase
II inhibitors [nalidixic acid, oxolinic acid, 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucop yra noside) (etoposide), 4'-demethylepipodophyllotoxin-thenylidene-beta-D-glucoside (teniposide), 1,4-dihydroxy-5,8-bis ((2-[(2-hydroxyethyl)amino]ethyl)amino)-9,10-anthracenedione (mitoxantrone), 5-(N-phenyl-carboxamido)-2-thiobarbituric acid (merbarone) or 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)], it did not lower K50 values determined for
topoisomerase
II-specific drugs in separate experiments. The effects observed can be classified according to the mechanism of action the inhibitors exhibit. (i) Novobiocin and coumermycin, inhibitors of the ATPase subunit of
topoisomerase
II, completely reduced DNA repair synthesis. (ii) Inhibition of repair was also found for ethidium bromide, quinacrine and distamycin, drugs known to modify the DNA substrate by intercalation or binding to the DNA minor groove. (iii) Inhibitors acting through intercalation and, simultaneously, binding to the cleavable DNA-
topoisomerase
complex (m-AMSA, mitoxantrone, doxorubicin and daunorubicin) also suppressed reparative DNA synthesis. (iv) Only small effects were observed for etoposide, nalidixic acid and oxolinic acid, whereas teniposide caused marked inhibition of DNA repair synthesis. (v) Merbarone, a novel type of
topoisomerase
II inhibitor, blocked UV-induced DNA repair drastically. The results are best explained by assuming that in UV-irradiated human fibroblasts the 180 kDa form of
topoisomerase
II is the main target enzyme for inhibitors which suppressed DNA excision repair and that this isozyme is involved in steps preceding repair-specific DNA incision.
Carcinogenesis 1992
Dec
PMID:The function of DNA topoisomerases in UV-induced DNA excision repair: studies with specific inhibitors in permeabilized human fibroblasts. 133 77
Plumbagin and shikonin, plant metabolites which have naphthoquinone structures, induced mammalian
topoisomerase
II-mediated DNA cleavage in vitro. Treatment of a reaction mixture containing these naphthoquinones and
topoisomerase
II at an elevated temperature (65 degrees C) resulted in a great reduction in DNA cleavage, suggesting that the mechanism of the
topoisomerase
II-mediated DNA cleavage induced by these naphthoquinones is through formation of a cleavable complex, as seen with antitumor agents such as 4'-(9-acridinylamino)methanesulfon-m-anisidide and demethylepipodophyllotoxin ethylidene-beta-glucoside. Lawson and lapacol, which are structurally related plant metabolites with naphthoquinone moieties, could not induce
topoisomerase
II-mediated DNA cleavage. Plumbagin and shikonin induced a similar DNA cleavage pattern with
topoisomerase
II which was different from the cleavage patterns induced with other known
topoisomerase
II-active drugs. A DNA-unwinding assay with T4 DNA ligase showed that shikonin, lawson, and lapacol did not intercalate into DNA, while plumbagin and 2-methyl-1,4-naphthoquinone intercalate into DNA, but to a lower degree than 4'-(9-acridinylamino)methanesulfon-m-anisidide does.
Antimicrob Agents Chemother 1992
Dec
PMID:Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin. 133 38
DNA topoisomerases, a class of enzymes that change the topological structure of DNA, have been shown to be the target of many therapeutic agents, including antibacterial agents (quinolones) and anticancer agents. These drugs inhibit the enzyme in a unique way so that the enzyme is converted into a cellular poison. Candida albicans and Aspergillus niger are two major opportunistic fungal pathogens. Our results show that these fungi have high levels of both type I and type II topoisomerases (with a minimum of 5 x 10(5) ATP-independent relaxation units and 2 x 10(5) P-4 unknotting units per liter of wild-type C. albicans). The ATP-dependent type II
topoisomerase
(termed C. albicans
topoisomerase
II) was purified by approximately 2,000-fold from C. albicans cells by using a simple isolation scheme that consists of three column procedures: hydroxylapatite, phosphocellulose, and heparin-agarose chromatographies. The responses of the Candida and the calf thymus
topoisomerase
II to some known
topoisomerase
II inhibitors were measured. Etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide, compounds known to inhibit catalysis and to enhance DNA breakage by mammalian
topoisomerase
II, and A-80198, an etoposide derivative, enhanced cleavage by both enzymes at similar concentrations of these compounds, with the response of the calf thymus
topoisomerase
II from slightly to fourfold higher in magnitude than the response of the Candida enzyme in the same concentration range. In contrast, A-75272 (a cytotoxic tricyclic quinolone) shows a slightly stronger DNA cleavage enhancement effect with the Candida enzyme than with the mammalian counterpart. The abundance of the enzyme in cells and the different drug responses of the host enzyme and the fungal enzyme suggest that the fungal
topoisomerase
may serve as a target for the discovery of effective and safe antifungal agents.
Antimicrob Agents Chemother 1992
Dec
PMID:DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. 133 49
Etoposide remains an integral component of therapy for non-small cell lung cancer. Its single-agent activity, and, hence, its activity in combination therapy, need to be reassessed in light of several reports of increased activity at higher doses. Although no effective means of overcoming resistance to etoposide appear to exist,
topoisomerase
II levels may predict sensitivity to treatment. Biologic response modifiers appear to add little or nothing to standard etoposide chemotherapy for non-small cell lung cancer. Continuous low-dose etoposide infusions do not appear to exhibit the same degree of activity as has been observed with prolonged oral dosing. The availability of effective means of reducing hematologic and emetic side effects of chemotherapy may permit rational trials of more intensive therapy.
Semin Oncol 1992
Dec
PMID:The role of standard-dose etoposide in the management of non-small cell lung cancer. 133 19
GAP 31, DAP 32 and DAP 30 comprise a new class of plant proteins with potent anti-HIV activity and insignificant cytotoxicity. We report here the identification and characterization of a new DNA enzyme activity in these three proteins. They irreversibly relax and decatenate supercoiled DNA, as well as catalyze double-stranded breakage to form linear DNA. The relaxed molecules are topologically inactive and no longer serve as substrates for DNA gyrase to form supercoils, phenomena similar to those of cellular topoisomerases in the presence of
topoisomerase
poisons. The ability of these anti-HIV agents to interrupt essential topological interconversions of DNA may provide a novel mechanism for their antiviral and antitumor actions. The presence of this new DNA topological enzyme activity in these plant proteins also suggests that their anti-HIV activity may not be merely a consequence of ribosome inactivation previously recognized.
Biofactors 1992
Dec
PMID:Anti-HIV plant proteins catalyze topological changes of DNA into inactive forms. 133 69
The replication of pT181 and related plasmids of Staphylococcus aureus proceeds by a rolling circle mechanisms. The initiator proteins encoded by the plasmids of the pT181 family have sequence-specific DNA binding and
topoisomerase
activities. These proteins nick one strand of the DNA at the origin of replication. The free 3'-hydroxyl end at the nick is then used as a primer for the replication of the leading strand of the DNA. Although these initiator proteins are highly homologous, they show specificity in DNA binding and replication for their cognate DNAs. In this study, we have generated hybrid initiator proteins and studied their various biochemical activities in vitro. Our results show that 6 amino acids are sufficient to determine the DNA binding and replication specificities of such initiator proteins.
J Biol Chem 1992
Dec
05
PMID:Six amino acids determine the sequence-specific DNA binding and replication specificity of the initiator proteins of the pT181 family. 144 99
Blood sera of patients with autoimmune diseases scleroderma (Scl), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) have been shown to yield a specific immune response to topoisomerase I, the product of expression of a cDNA fragment cloned into lambda gt11 and monoclonal antibodies (MAB) to the enzyme. The '
topoisomerase
test' is not absolutely specific for Scl. The stable positive response of autoimmune sera to anti-
topoisomerase
monoclonal antibodies has a specific character and is associated with the interaction of the Fab fragment of MAB with the IgG fraction of autoimmune serum. The response observed indicates the induction of anti-idiotypic antibodies against
topoisomerase
. The anti-idiotype, isolated by HPLC and affinity chromatography demonstrated the following functional activities: (i) the immunological reaction against DNA; (ii) high-affinity DNA-binding with
topoisomerase
-specific consensus; (iii) ability to compete with the native enzyme for binding with DNA and MAB to
topoisomerase
; (iv) immunological reaction against MAB to
topoisomerase
.
FEBS Lett 1992
Dec
21
PMID:DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. 146 55
Fluoroquinolones are potent inhibitors of bacterial
topoisomerase
II (DNA gyrase). They can also inhibit eukaryotic topoisomerases, which could possibly lead to clastogenicity and/or cellular toxicity. Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the fluoroquinolones and the potential of these compounds to induce micronuclei, a genetic toxicity endpoint. In an effort to identify potent nontoxic quinolone antibacterials, we have examined the structural features of the fluoroquinolones associated with mammalian cell cytotoxicity. An investigation of a wide variety of substituents at the 1, 5, 7, and 8 positions of a quinolone nucleus was conducted. The results indicate that no one position has a controlling effect on the observed cytotoxicity. Instead, a combination of the various substituents contributes to the effects seen. Certain trends were apparent, such as the fact that compounds with pyrrolidines at the R-7 position were more cytotoxic than those with piperazines, and halogens at R-8 (X-position) were associated with more cytotoxicity relative to hydrogen. A general trend also existed between the cytotoxicity of the compounds and their Gram-positive antibacterial activity. A detailed comparison between the various groups and positional variations as they controlled the cytotoxicity and antibacterial activity is presented.
J Med Chem 1992
Dec
11
PMID:Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. 146 2
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>